Manufacturer of Controlled Substances; Notice of Application, 16719 [E8-6359]

Agencies

• Drug Enforcement Administration
• Department of Justice

[Federal Register Volume 73, Number 61 (Friday, March 28, 2008)]
[Notices]
[Page 16719]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-6359]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a), Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on February 29, 2008, Alltech 
Associates Inc., 2051 Waukegan Road, Deerfield, Illinois 60015, made 
application to the Drug Enforcement Administration (DEA) to be 
registered as a bulk manufacturer of the basic classes of controlled 
substances listed in schedule I and II:

------------------------------------------------------------------------
                       Drug                               Schedule
------------------------------------------------------------------------
Methcathinone (1237).............................  I
N-Ethylamphetamine (1475)........................  I
N,N-Dimethylamphetamine (1480)...................  I
4-Methylaminorex (cis isomer) (1590).............  I
Alpha-ethyltryptamine (7249).....................  I
Lysergic acid diethylamide (7315)................  I
2,5-Dimethoxy-4-(n)-propylthiophenethylamine       I
 (7348).
Tetrahydrocannabinols (7370).....................  I
Mescaline (7381).................................  I
4-Bromo-2,5-dimethoxyamphetamine (7391)..........  I
4-Bromo-2,5-dimethoxyphenethylamine (7392).......  I
4-Methyl-2,5-dimethoxyamphetamine (7395).........  I
2,5-Dimethoxyamphetamine (7396)..................  I
2,5-Dimethoxy-4-ethylamphetamine (7399)..........  I
3,4-Methylenedioxyamphetamine (7400).............  I
N-Hydroxy-3,4-methylenedioxyamphetamine (7402)...  I
3,4-Methylenedioxy-N-ethylamphetamine (7404).....  I
3,4-Methylenedioxymethamphetamine (MDMA) (7405)..  I
4-Methoxyamphetamine (7411)......................  I
Alpha-methyltryptamine (7432)....................  I
Bufotenine (7433)................................  I
Diethyltryptamine (7434).........................  I
Dimethyltryptamine (7435)........................  I
Psilocybin (7437)................................  I
Psilocyn (7438)..................................  I
5-Methoxy-N,N-diisopropyltryptamine (7439).......  I
N-Ethyl-1-phenylcyclohexylamine (7455)...........  I
1-(1-Phenylcyclohexyl) pyrrolidine (7458)........  I
1-Phenylcyclohexylamine (7460)...................  I
1-[1-(2-Thienyl) cyclohexy] piperidine (7470)....  I
Normorphine (9313)...............................  I
Methamphetamine (1105)...........................  II
Phencyclidine (7471).............................  II
Phenylacetone (8501).............................  II
1-Piperidinocyclohexanecarbonitrile (8603).......  II
Cocaine (9041)...................................  II
Codeine (9050)...................................  II
Dihydrocodeine (9120)............................  II
Dihydromorphine (9145)...........................  II
Ecgonine (9180)..................................  II
Meperidine intermediate-B (9233).................  II
Noroxymorphone (9668)............................  II
------------------------------------------------------------------------

    The company plans to manufacture high purity drug standards used 
for analytical application only in clinical, toxicological, and 
forensic laboratories.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substance may file comments or objections 
to the issuance of the proposed registration pursuant to 21 CFR 
1301.33(a). Any such comments or objections being sent via regular mail 
should be addressed, in quintuplicate, to the Drug Enforcement 
Administration, Office of Diversion Control, Federal Register 
Representative (ODL), Washington, DC 20537; or any being sent via 
express mail should be sent to Drug Enforcement Administration, Office 
of Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than May 27, 2008.

    Dated: March 19, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
 [FR Doc. E8-6359 Filed 3-27-08; 8:45 am]
BILLING CODE 4410-09-P